ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) is suited for growth investing. Investors should of course do their own research, but we spotted ARCTURUS THERAPEUTICS HOLDIN showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Key Considerations for Growth Investors.

• With a solid Return on Equity (ROE) of 35.45%, ARCTURUS THERAPEUTICS HOLDIN exemplifies its ability to generate favorable returns on shareholder investments. This metric demonstrates the company's commitment to maximizing shareholder value.
• ARCTURUS THERAPEUTICS HOLDIN has surpassed EPS estimates 3 times in the last 4 quarters, reflecting its strong financial performance and effective management. This trend suggests the company's ability to generate positive earnings surprises and drive shareholder value.
• With impressive 1-year revenue growth of 475.0%, ARCTURUS THERAPEUTICS HOLDIN showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
• The recent q2q revenue growth of 237.0% of ARCTURUS THERAPEUTICS HOLDIN showcases the company's ability to generate increasing revenue in a short period, reflecting its positive growth trajectory.
• The operating margin of ARCTURUS THERAPEUTICS HOLDIN has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
• The free cash flow (FCF) of ARCTURUS THERAPEUTICS HOLDIN has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows.
• With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), ARCTURUS THERAPEUTICS HOLDIN highlights its ability to generate increasing profitability, showcasing a 54.14% growth.
• Over the past 3 months, analysts have adjusted their EPS Estimate for ARCTURUS THERAPEUTICS HOLDIN with a 20.5% change. This highlights the evolving outlook on the company's EPS potential.
• The quarterly earnings of ARCTURUS THERAPEUTICS HOLDIN have shown a 54.14% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• ARCTURUS THERAPEUTICS HOLDIN shows accelerating EPS growth: when comparing the current Q2Q growth of 54.14% to the previous year Q2Q growth of 35.12%, we see the growth rate improving.

How does the complete fundamental picture look for NASDAQ:ARCT?

As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.

We assign a fundamental rating of 6 out of 10 to ARCT. ARCT was compared to 605 industry peers in the Biotechnology industry. While ARCT has a great health rating, its profitability is only average at the moment. ARCT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!

Our latest full fundamental report of ARCT contains the most current fundamental analsysis.

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.